Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 59, Issue 5, 1999, Pages 335-341

  Kleinveld, Henne A ^a   Andersson, N E ^b   Van Voorthuizen, H ^c   Den Hartog, J ^d   De Groot, P G ^d  

^a Sittard Geleen Heerlen   (Netherlands)

^b Chromogenix AB   (Sweden)

^c Nodia BV   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chromogenic substrate; Evaluation; Factor VIII assay; Hemophilia; STA automated coagulation analyzer

Indexed keywords

BLOOD CLOTTING FACTOR 8; CHROMOGENIC SUBSTRATE;

ACCURACY; ARTICLE; ASSAY; AUTOMATION; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPRODUCIBILITY; VALIDATION PROCESS;

EID: 0032877592     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519950185526     Document Type: Article

References (12)

1. Roberts RR. Hoffman M. Hemophilia and related conditions. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill, 1995: 1413-39.
2. Rosen S, Andersson M, Blomback M, Hagglund U, Larrieu MJ, Wolf M, et al. Clinical application of a chromogenic substrate method determination of factor VIII activity. Thromb Haemost 1985; 54: 818-23.
3. Mertens K, van Wijngaarden A, Bertina RM. The role of factor VIII in the activation of blood coagulation factor X by activated factor IX. Thromb Haemost 1985; 54: 654-60.
4. Roddie PH, Ludlam CA. Recombinant coagulation factors. Blood Rev 1997; 11: 169-77.
5. Pasi KJ. Previously untreated patients and recombinant factor VIII concentrate studies. Blood Coagul Fibrinolysis 1997; 8: S29-32.
6. Hellstern P, Faller B, Haas FJLM, van Sterkenburg B, Speiser W, Handler S, et al. Multicenter evaluation of the STA analyzer. Klin Lab 1994; 40: 509-22.
7. Barrowcliffe TW. Clotting factor concentrates in clinical practice. Standardization and assay. Semin Thromb Hemost 1993; 19: 73-9.
8. Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 1989; 19: 131-7.
9. Kasper CK, Aronson DL, Davignon G, Foster P, Hillman-Wiseman C, Lusher JM, et al. Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. Thromb Haemost 1998; 74: 987-9.
10. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemofilia A. Br J Haematol 1994; 87: 846-8.
11. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII: C methods. Br J Haematol 1996; 94: 400-6.
12. Lee C, Barrowclifle T, Bray G, Gomperts E, Hubbard A, Kemball-Cook G. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996; 76: 950-6.